Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting
Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…Abstract Number: 2674 • 2017 ACR/ARHP Annual Meeting
The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over…Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…Abstract Number: 2690 • 2017 ACR/ARHP Annual Meeting
Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Background/Purpose: D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in…Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting
Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…Abstract Number: 2691 • 2017 ACR/ARHP Annual Meeting
Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a chronic systemic disease characterized by skin and internal organs fibrosis along with vasculopathy. Previous studies have reported increased cadherin-11…Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting
Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…Abstract Number: 2695 • 2017 ACR/ARHP Annual Meeting
Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Background/Purpose: A common and distressing manifestation of systemic sclerosis (SSc, or scleroderma) is disfigurement in socially relevant areas of the body, including the face and…Abstract Number: 733 • 2017 ACR/ARHP Annual Meeting
Ethnic Variation in Systemic Sclerosis Morbidity and Mortality
Background/Purpose: Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by pathological skin thickening and can involve multiple internal organs. Ethnic variations in SSc…Abstract Number: 2696 • 2017 ACR/ARHP Annual Meeting
Things Left Unsaid: Important Topics That Are Not Discussed between Patients with Systemic Sclerosis, Their Carers and Their Healthcare Professionals
Background/Purpose: Systemic sclerosis (SSc) is a serious rare condition that can be complicated by internal organ damage including interstitial lung fibrosis (SSc-ILD), which is a…Abstract Number: 737 • 2017 ACR/ARHP Annual Meeting
Dynamic Prediction of Pulmonary Hypertension Development in Systemic Sclerosis Patients Using Landmark Analysis – Comparison of Two Models
Background/Purpose: Pulmonary hypertension (PH) contributes substantially to systemic sclerosis (SSc)-related morbidity and mortality. It tends to develop later in the disease, creating an opportunity for…Abstract Number: 2982 • 2017 ACR/ARHP Annual Meeting
Morbidity and Mortality of Scleroderma in African Americans
Background/Purpose: Retrospective cohorts have demonstrated that African Americans (AAs) with scleroderma are more likely to have severe disease and higher mortality than non-AAs. A prior…Abstract Number: 761 • 2017 ACR/ARHP Annual Meeting
Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis
Background/Purpose: The TNF Superfamily member LIGHT (TNFSF14) regulates immune response and angiogenesis. Moreover, recent studies indicate that interactions of LIGHT with its receptor, TNFRSF14, might…Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…Abstract Number: 1189 • 2016 ACR/ARHP Annual Meeting
Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »